IL17A and diabetic kidney disease: Furthermore, the administration of IL-17 neutralizing antibodies has been shown to reduce glomerular injury, preserve podocyte numbers, and ameliorate proteinuria in experimental models of diabetic nephropathy (127, 128, 140).